Long-term immunological benefit in patients with discordant responses to therapy depends on both level of viremia and duration of rebound.
Open Access
- 1 August 2002
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (3) , 445-446
- https://doi.org/10.1086/341461
Abstract
To the Editor —The article by Le Moing et al. [1], which reports the results of the large French Antiprotéase Cohort after 24 months of observation, provides important information that may help the clinician who is faced with the dilemma of maintaining or modifying antiretroviral treatment for those patients with satisfactory immunological response to highly active antiretroviral therapy (HAART) in the presence of replicating virus. Nevertheless, Le Moing et al. correctly point out that longer follow-up is needed to confirm the long-term clinical implications of maintaining the current protease inhibitor (PI)–based regimen for patients with low-level viremia. Furthermore, other authors do not recommend such an approach because of the fear of accumulation of drug-specific resistance mutations [2]Keywords
This publication has 0 references indexed in Scilit: